CHILDRENS CANCER GROUP

在儿童癌症方面取得了巨大进展，包括更有效的治疗、对这些疾病的生物学的深入了解、对病因的更明确定义以及对这些疾病幸存者的结局的新关注。这些成果在很大程度上是由合作临床试验小组促成的。这笔拨款将促进明尼苏达大学的研究人员继续参与儿童癌症小组（CCG）开展的多机构合作治疗性和非治疗性研究。在过去的资助周期中，明尼苏达的研究人员一直处于所有这些领域的最前沿，并准备在未来继续这种富有成效的关系。1997年，明尼苏达联盟注册了162名患者进行治疗性试验（I、II和III期），此外，注册了近100名患者进行非治疗性（生物学、流行病学）研究。强大的患者累积、数据管理、小组领导和CCG出版物的作者身份相结合，使明尼苏达州在1995年、1996年和1997年在所有小组机构中排名第一。明尼苏达大学的研究人员在流行病学和癌症控制、造血干细胞移植、急性淋巴母细胞和急性髓性白血病、生物学和实验治疗学方面继续发挥着强有力的领导作用。在过去的拨款周期中，明尼苏达的研究人员主持了14个小组治疗或科学委员会，并在另外24个小组中担任副主席。明尼苏达一直领导小组在第一作者的小组出版物。干细胞移植、流行病学和癌症控制、实验疗法和生物学的机构研究已应用于小组研究，所有这些领域的未来调查正在发展中。这项奖助金要求支援对我们未来团体活动至关重要的人员。它将确保数据管理的持续卓越，允许调查人员和其他关键人员前往小组会议，并为小组研究的患者累积所产生的费用提供所需的资金。这笔资金将确保明尼苏达州的研究人员在未来五年内继续在儿童癌症小组的各个方面发挥领导作用。

Dramatic gains have been made in childhood cancer including markedly more effective therapy, insights into the biology of these diseases, a clearer definition of etiologic factors, and a new focus on the outcomes of the survivors of these diseases. These gains have largely been facilitated by the cooperative clinical trials groups. This grant will facilitate the continued involvement of the investigators at the University of Minnesota in the multi-institutional cooperative therapeutic and non- therapeutic studies conducted by the Children's Cancer Group (CCG). Minnesota investigators have been at the forefront of all of these venues over the past grant cycle and are poised to continue this productive relationship into the future. In 1997, the Minnesota consortium registered 162 patients on therapeutic trials (phase I, II, and III) and, in addition, registered patients on almost 100 non-therapeutic (biology, epidemiology) studies. The combination of strong patient accrual, data management, group leadership, and authorship of CCG publications resulted in Minnesota being ranked first among all group institutions in 1995, 1996, and 1997. Minnesota investigators have continued strong leadership roles in Epidemiology and Cancer Control, Hematopoetic Stem Cell Transplantation, acute lymphoblastic and acute myeloid leukemia, biology, and experimental therapeutics. Over the past grant cycle, Minnesota investigators have chaired fourteen group therapeutic or scientific committees and served as vice-chairs on an additional twenty four. Minnesota has consistently led the group in first- authorship of group publications. Institutional research in stem cell transplantation, epidemiology and cancer control, experimental therapeutics, and biology has been applied to group studies and future investigations of all of these areas are under development. This grant requests support for the personnel critical to our future group activities. It will assure continued excellence in data management, allow travel by investigators and other key personnel to group meetings, and supply the funds needed for expenses generated by the accrual of patients to group studies. This funding will assure the continued leadership of Minnesota investigators in all aspects of the Children's Cancer Group over the coming five years.